Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1988 1
1989 6
1990 5
1991 5
1995 1
1996 2
1997 2
1998 6
1999 2
2001 1
2003 1
2004 1
2007 2
2008 2
2009 4
2016 1
2017 1
2018 3
2020 3
2021 6
2022 8
2023 5
2024 5
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K. Miura K, et al. Among authors: hamai k. J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2618-2628. doi: 10.1002/jcsm.13606. Epub 2024 Oct 1. J Cachexia Sarcopenia Muscle. 2024. PMID: 39351653 Free PMC article.
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N. Ishihara M, et al. Among authors: hamai k. Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344010. doi: 10.1177/17588359251344010. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40535732 Free PMC article.
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K. Murata D, et al. Among authors: hamai k. Lung Cancer. 2025 Nov;209:108772. doi: 10.1016/j.lungcan.2025.108772. Epub 2025 Sep 26. Lung Cancer. 2025. PMID: 41046781
[Familial Mediterranean fever].
Hamai K, Miura AB. Hamai K, et al. Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):496-8. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9851199 Review. Japanese. No abstract available.
Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.
Tozuka T, Tsukita Y, Kushiro K, Hosokawa S, Nogawa H, Arai S, Soda S, Arai D, Takamura K, Honda R, Hamai K, Namba Y, Kawai Y, Kikuchi T, Nakazawa K, Honda T, Ebi N, Yamada Y, Makiguchi T, Seike M, Morita S, Kobayashi K, Asahina H. Tozuka T, et al. Among authors: hamai k. Int J Clin Oncol. 2025 Dec;30(12):2523-2531. doi: 10.1007/s10147-025-02911-1. Epub 2025 Nov 5. Int J Clin Oncol. 2025. PMID: 41191235
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Tachihara M, Nakatani T, Harada T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Yoshizumi Y, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Mamesaya N, Misumi T, Matsutani N, Seki N. Ishihara M, et al. Among authors: hamai k. JTO Clin Res Rep. 2026 Feb 12;7(4):100972. doi: 10.1016/j.jtocrr.2026.100972. eCollection 2026 Apr. JTO Clin Res Rep. 2026. PMID: 41938081 Free PMC article.
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study.
Tsubata Y, Hotta T, Hamai K, Furuya N, Yokoyama T, Saito R, Nakamura A, Masuda T, Hamaguchi M, Kuyama S, Honda R, Senoo T, Nakanishi M, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: hamai k. J Hematol Oncol. 2022 Apr 4;15(1):40. doi: 10.1186/s13045-022-01259-7. J Hematol Oncol. 2022. PMID: 35379309 Free PMC article.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T, Nogami S, Yamamoto N, Nakagawa K, Hattori N. Masuda T, et al. Among authors: hamai k. Sci Rep. 2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3. Sci Rep. 2023. PMID: 37957228 Free PMC article.
Late onset bone marrow transplant nephropathy.
Oyama Y, Komatsuda A, Imai H, Ohtani H, Hamai K, Wakui H, Miura AB, Nakamoto Y. Oyama Y, et al. Among authors: hamai k. Intern Med. 1996 Jun;35(6):489-93. doi: 10.2169/internalmedicine.35.489. Intern Med. 1996. PMID: 8835602 Free article. Review.
75 results